Media Coverage
Media Coverage
Press Contacts: Erik Cummins, Matt Hyams, Olivia Thomas
01.19.23
Pillsbury advised NEUCA Group, the parent company of Clinscience, a European CRO, in a partnership with OncoBay, a boutique CRO specializing in custom solutions for biotechnology companies developing complex immuno-oncology therapies.
Clinscience and OncoBay have collaborated extensively over the past two years and together are currently advancing several dozen immuno-oncology projects. The transaction, which gave holding company Neuca Clinical Trials Inc. a majority equity stake in OncoBay, will further expand their relationship and allow Clinscience and OncoBay to provide comprehensive support to their clients on a global scale. OncoBay will benefit from Clinscience’s robust data management and technology services, while Clinscience will strengthen its presence in the U.S. biotechnology market and gain greater access to U.S. clinical trials.
The Pillsbury deal team included Corporate partner Stan Lewandowski, counsel Mediha Ali and associate Jake Sendar, Tax senior counsel Laura Watts and Insurance Recovery & Advisory counsel Aaron Coombs.
Click here to learn more about the partnership.